HIG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hartford Insurance Group (HIG) is not a strong buy right now for a beginner long-term investor, but it is a reasonable hold if already owned. The stock has solid fundamentals and improving quarterly earnings, yet the technical picture is weak-to-neutral, options sentiment is mixed, and recent analyst estimates have been trimmed after a Q1 miss. Since the investor is impatient and does not want to wait for a better entry, I would not start a new position at this moment.
HIG is trading pre-market around 137.41, just above the pivot level of 137.772 and below the next resistance at 140.755. RSI_6 is 45.71, which is neutral, and the MACD histogram is -0.21 and still weakening, signaling short-term downside pressure. Moving averages are converging, which suggests a lack of strong trend direction. Overall, the chart is range-bound with mild bearish momentum, not an ideal immediate entry.
["Q1 2026 revenue rose 6.19% YoY to 7.243B.", "Net income increased 36.16% YoY to 851M.", "EPS grew 41.40% YoY to 3.04.", "News noted 6% growth in written premiums and $551M core earnings in Q1 2026.", "Dividend payout supports the income-oriented appeal of the stock.", "Hedge funds are buying, with buying up 324.87% over the last quarter."]
["Q1 results missed consensus, which pressured the stock.", "Legacy reserve charge and higher expense ratios weighed on earnings quality.", "Analysts have lowered price targets recently despite mostly constructive ratings.", "Insiders are selling sharply, with selling up 4334.85% over the last month.", "Premium growth and broker organic growth are described as sluggish.", "Technical momentum is weak, with a negative MACD histogram and neutral RSI."]
In Q1 2026, Hartford showed strong growth momentum: revenue increased 6.19% YoY to 7.243B, net income rose 36.16% YoY to 851M, and EPS climbed 41.40% YoY to 3.04. The latest quarter is Q1 2026, and the main weakness was that reported results still missed expectations due to a legacy reserve charge and higher expense ratios. The underlying growth trend remains healthy, but execution quality was mixed in the latest quarter.
Recent analyst sentiment remains mostly positive but slightly less confident after Q1. Raymond James, Mizuho, UBS, Barclays, and Cantor Fitzgerald all maintained constructive ratings, but several trimmed price targets. Keefe Bruyette downgraded the stock to Market Perform on reserve adequacy concerns, while BofA and Citi stayed neutral. Wall Street's pro view: strong underwriting, above-peer ROEs, and capital return potential. Wall Street's con view: reserve concerns, a recent earnings miss, sluggish premium growth, and some pressure on expense ratios.
